Skip to main content

Advertisement

Table 2 Clinical/oocyte/embryo parameters from ovarian stimulation to embryo transfer relationship between serum progesterone levels and clinical pregnancy rates

From: Letrozole supplementation during controlled ovarian stimulation in expected high responders: a pilot randomized controlled study

  Group A Group B Wilcoxon W/t/X2 P
Patients with P elevation on day of administraition day n(%) 15.4% (10/65) 7.7% (5/65) 1.884 0.170
RecFSH 1275 (0,2700) 1350 (787.52175) −0.703 0.482
RecFSH/day 137.5 (0,225) 142.5 (98.44,197.73) −1.735 0.083
Recovery rate of eggs 13 (1,28) 12 (3,34) −1.516 0.129
Duration of GN(day) 9 (6,19) 9 (7,13) −1.293 0.196
Fertilized egg number 8.72 ± 4.26 8.63 ± 4.15 0.132 0.895
Fertilization rate 69.2% (0,100%) 78.5% (0,100%) −1.493 0.135
Number of cleavage 8.57 ± 4.23 8.53 ± 4.19 0.051 0.959
Cleavage rate 100% (100,100%) 100% (100,100%)   
High-quality embryo 5 (0,13) 6 (0,14) −0.879 0.379
Rate of production of high-quality embryos 60% (0,100%) 70% (0,100%) −1.21 0.226
P on the day of hCG administration (ng/mL) 1.05 (0.3,2.61) 0.95 (0.15,2.06) −2.047 0.041
E2 on the day of hCG administration (pg/mL) 1404.28 (431.36227) 2867 (1043.62,7198) −7.131 < 0.001
P/E2 on the day of hCG administration 0.73 (0.066,1.86) 0.317 (0.043,1.84) −6.931 < 0.001
E2 on 1 day before the day of hCG administration 546.95 (0,2611) 1102 (0,5488) −2.055 0.040
P on 1 day before the day of hCG administration 0.545 (0,1.65) 0.52 (0,1.83) −0.33 0.741
P on 6th day post-ET (ng/mL) 9.025 (0,96.3) 9.08 (0,44.86) −0.407 0.984
E2 on 6th day post-ET (ng/mL) 103.4 (0,4737) 127.75 (0,2656) −0.158 0.875
Thickness of endometrium 12.1 (9,17) 12.2 (8.3,17.8) −0.284 0.776
Clinical pregnancy rate 53.1% (26/49) 72.9% (35/48) 4.096 0.043
Implantation rate 35.1% (33/94) 47.4% (45/95) 2.931 0.087
Incidence of OHSS 0% (0/65) 1.5% (1/65) 1.008 1.000
Live birth rate 42.9% (21/49) 62.5% (30/48) 3.752 0.053
First trimester miscarriage 7.7% (2/26) 5.7% (2/35) 0.095 1.000
Second trimester miscarriage 7.7% (2/26) 5.7% (2/35) 0.095 1.000
  1. Note: quantitative indicators subject to normal distribution were presented as mean ± standard deviation. Median (Min, Max) was not used to describe the normal distribution. Group A: letrozole 2.5 mg/day from cycle day 5 to the day before hCG administration. Group B: no letrozole; ET Embryo transfer, RecFSH Recombinant FSH, OHSS Ovarian hyperstimulation syndrome